Objective:

To assess the neutralizing activity of antibodies in saliva against the spike receptor-binding domain (RBD) of SARS-CoV-2 and its Omicron variant using a surrogate virus neutralization test (sVNT).

Approach:

Key Findings:

• The analytical sensitivity and specificity of the laboratory-developed sVNT are comparable to FDA-approved tests.
• Vaccine-elicited saliva antibodies effectively blocked the binding of hACE-2 to the spike RBD of the reference strain.
• The Omicron variant spike RBD abolished the neutralizing ability of saliva antibodies.

Interpretation:

The findings suggest that the Omicron variant can escape mucosal immune defense, highlighting challenges in neutralization.

Limitations:

• The study focused on a specific population that received the Pfizer vaccine.
• The implications of findings on broader populations or other vaccines were not assessed.

Conclusion:

The study demonstrates the potential of using sVNT to evaluate immune protection against SARS-CoV-2 and possibly other pathogens.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.